SG11201805591QA - Tacrolimus for treating tdp-43 proteinopathy - Google Patents

Tacrolimus for treating tdp-43 proteinopathy

Info

Publication number
SG11201805591QA
SG11201805591QA SG11201805591QA SG11201805591QA SG11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA
Authority
SG
Singapore
Prior art keywords
international
tacrolimus
rdc5
proteinopathy
street
Prior art date
Application number
SG11201805591QA
Inventor
Pete Appleford
Huw Jones
Helen Kuhlman
Julia Sherriff
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Publication of SG11201805591QA publication Critical patent/SG11201805591QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization International Bureau .. .... ..Yejd (43) International Publication Date ..... .....1 13 July 2017 (13.07.2017) WI P0 I P CT IIIM141101110101011111 HO 11111011130111111111111110011111111101111 III N (10) International Publication Number WO 2017/118857 Al (51) (21) (22) (25) (26) (30) (71) (72) (74) International Patent Classification: A61K 31/436 (2006.01) A61P 25/28 (2006.01) International Application Number: International Filing Date: Filing Language: Publication Language: Priority Data: 1600376.6 8 January 2016 (81) Designated States (unless otherwise indicated, for every A61P 25/16 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB2017/050021 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 6 January 2017 (06.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (08.01.2016) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, LIMITED GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 41 Cornmarket Street, Oxford TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Pete; 40 Castle Road, Woot- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, JONES, Huw; The Old SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Morden, Royston Hert- GW, KM, ML, MR, NE, SN, TD, TG). Helen; 14 Somer- (GB). SHERRIFF, Julia; 5 Published: 8FF (GB). — with international search report (Art. 21(3)) Potter Clarkson LLP, Street, Nottingham NG1 5GG Applicant: CHRONOS THERAPEUTICS [GB/GB]; c/o Mercer Lewin, OX1 3HA (GB). Inventors: APPLEFORD, ton, Woodstock OX20 lEG (GB). School, 45 Church Street, Guilden fordshire SG8 OJD (GB). KUHLMAN, dale View, Bath BA2 2QQ Terrett Avenue, Oxford OX3 Agent: CARLING, David Andrew; The Belgrave Centre, Talbot (GB). Title: TACROLIMUS FOR TREATING TDP-43 PROTEINOPATHY 300 250 W — 200, >+ cu ... as 150 —I 100 50 : The present invention as amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTDs), wherein the tacrolimus is for administration at a -effective dose which (54) \" therapeutically Rotarod Performance over 60 weeks V 4 f 4—. - — RDC5 0 25mg/kg — RDC5 1 25mg/kg R . ' T T1 — RDC5 2 5mg/kg I — Vehicle 1 — Non Tg TT T TT f i. l' k'`w r . Il .4 Ir ... ' 11 in GC Il Il IN 1-1 (57) 0 such 0 10 20 30 40 50 60 70 Week FIGURE 3 provides tacrolimus for use in the treatment in a human subject of a TDP-43 proteinopathy, does not cause immunosuppression in the subject.
SG11201805591QA 2016-01-08 2017-01-06 Tacrolimus for treating tdp-43 proteinopathy SG11201805591QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1600376.6A GB201600376D0 (en) 2016-01-08 2016-01-08 Novel therapeutic agents
PCT/GB2017/050021 WO2017118857A1 (en) 2016-01-08 2017-01-06 Tacrolimus for treating tdp-43 proteinopathy

Publications (1)

Publication Number Publication Date
SG11201805591QA true SG11201805591QA (en) 2018-07-30

Family

ID=55445754

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805591QA SG11201805591QA (en) 2016-01-08 2017-01-06 Tacrolimus for treating tdp-43 proteinopathy

Country Status (10)

Country Link
US (1) US20190015395A1 (en)
EP (1) EP3399977A1 (en)
JP (1) JP2019501972A (en)
KR (1) KR20180102086A (en)
CN (1) CN108601772A (en)
AU (1) AU2017205162A1 (en)
CA (1) CA3010203A1 (en)
GB (1) GB201600376D0 (en)
SG (1) SG11201805591QA (en)
WO (1) WO2017118857A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728820D0 (en) 1987-12-09 1988-01-27 Fisons Plc Compounds
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
BRPI0413927B8 (en) 2003-08-29 2021-05-25 Lifecycle Pharma As pharmaceutical composition comprising tacrolimus, dosage form, use of the composition, and method for preparing the composition
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
RU2574006C2 (en) 2008-07-08 2016-01-27 Лайфсайкл Фарма А/С Tacrolimus for improved treatment of patients with grafts
LT2575769T (en) 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilized tacrolimus composition
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Also Published As

Publication number Publication date
US20190015395A1 (en) 2019-01-17
AU2017205162A1 (en) 2018-07-26
KR20180102086A (en) 2018-09-14
EP3399977A1 (en) 2018-11-14
GB201600376D0 (en) 2016-02-24
WO2017118857A1 (en) 2017-07-13
CN108601772A (en) 2018-09-28
JP2019501972A (en) 2019-01-24
CA3010203A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
SG11201900596XA (en) Cannabis composition
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900501RA (en) Cannabis composition
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201811559WA (en) Cancer treatment combinations
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201808949SA (en) Combinations and methods comprising a capsid assembly inhibitor
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds